Q2 FY26 results, 100% acquisition of Celliimune Biotech, Rs 10 Cr solar investment approved

Listed-company acquisitionStrategic Transactions View source PDF Explain this filing

CONCORDBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.2%Reaction day

₹1463.80

prior close

₹1390.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.2%+3.0% vs market

Pharmaceuticals peers, median of 157sector+0.0%+3.2% vs sector

On the reaction day the stock moved 3.0 pts more than Nifty Smallcap 250 and 3.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+4.5

10m

+5.5

15m

+5.3

30m

+4.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.2+0.2+3.0+0.0+3.2

Next day

+2.5+0.9+1.6-0.1+2.6

+2.5-0.2+2.6-0.9+3.4

-1.2-0.6-0.6-1.4+0.2

-1.5-0.7-0.8-1.6+0.1

-2.7-1.9-0.8-2.3-0.5

-4.2-2.4-1.7-2.9-1.3

15d

-3.7-3.3-0.5-3.1-0.7

-7.1-3.5-3.6-4.3-2.8

-7.7-4.5-3.2-5.6-2.1

-20.6-6.3-14.4-10.3-10.4

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q2 FY26 results: standalone revenue Rs 247.06 Cr, PAT Rs 62.90 Cr versus Rs 310.18 Cr and Rs 98.70 Cr in Q2 FY25, EPS Rs 6.01. H1 revenue Rs 451.05 Cr, PAT Rs 105.46 Cr. Also approved 100 percent acquisition of Celliimune Biotech as a related party deal and Rs 10 Cr investment in a captive hybrid solar power project for the Limbasi plant. Statutory auditors issued an unmodified review opinion.

Likely market impact

Earnings declined year on year. Celliimune acquisition expands footprint but is a related party deal that may attract scrutiny. Solar capex supports long term energy costs.